EUVIMEDEUVIMED entdecken
Open Access

Kaposi sarcoma-associated herpesvirus complement control protein (KCP) and glycoprotein K8.1 are not required for viral infection in vitro or in vivo

Murali Muniraju iD, Lorraine Z Mutsvunguma, Ivana G Reidel, Gabriela M Escalante iD, Simeon Cua, Webster Musonda, Jonathan Calero-Landa, Mafalda A Farelo iD, Esther Rodriguez, Zhou Li, Javier Gordon Ogembo iD

Journal of Virology · 2024

DOI: 10.1128/jvi.00576-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Murali Muniraju und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA. Hauptthemen laut MEDLINE: Herpesvirus 8, Human, Viral Proteins, Sarcoma, Kaposi, Viral Envelope Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health (NIH), NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8, is the causal agent of Kaposi sarcoma, a cancer that appears as tumors on the skin or mucosal surfaces, as well as primary effusion lymphoma and KSHV-associated multicentric Castleman disease, which are B-cell lymphoproliferative disorders. Effective prophylactic and therapeutic strategies against KSHV infection and its associated diseases are needed. To develop these strategies, it is crucial to identify and target viral glycoproteins involved in KSHV infection of host cells. Multiple KSHV glycoproteins expressed on the viral envelope are thought to play a pivotal role in viral infection, but the infection mechanisms involving these glycoproteins remain largely unknown. We investigated the role of two KSHV envelope glycoproteins, KSHV complement control protein (KCP) and K8.1, in viral infection in various cell types in vitro and in vivo . Using our newly generated anti-KCP antibodies, previously characterized anti-K8.1 antibodies, and recombinant mutant KSHV viruses lacking KCP, K8.1, or both, we demonstrated the presence of KCP and K8.1 on the surface of both virions and KSHV-infected cells. We showed that KSHV lacking KCP and/or K8.1 remained infectious in KSHV-susceptible cell lines, including epithelial, endothelial, and fibroblast, when compared to wild-type recombinant KSHV. We also provide the first evidence that KSHV lacking K8.1 or both KCP and K8.1 can infect human B cells in vivo in a humanized mouse model. Thus, these results suggest that neither KCP nor K8.1 is required for KSHV infection of various host cell types and that these glycoproteins do not determine KSHV cell tropism. IMPORTANCE Kaposi sarcoma-associated herpesvirus (KSHV) is an oncogenic human gamma-herpesvirus associated with the endothelial malignancy Kaposi sarcoma and the lymphoproliferative disorders primary effusion lymphoma and multicentric Castleman disease. Determining how KSHV glycoproteins such as complement control protein (KCP) and K8.1 contribute to the establishment, persistence, and transmission of viral infection will be key for developing effective anti-viral vaccines and therapies to prevent and treat KSHV infection and KSHV-associated diseases. Using newly generated anti-KCP antibodies, previously characterized anti-K8.1 antibodies, and recombinant mutant KSHV viruses lacking KCP and/or K8.1, we show that KCP and K8.1 can be found on the surface of both virions and KSHV-infected cells. Furthermore, we show that KSHV lacking KCP and/or K8.1 remains infectious to diverse cell types susceptible to KSHV in vitro and to human B cells in vivo in a humanized mouse model, thus providing evidence that these viral glycoproteins are not required for KSHV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 8, HumanViral ProteinsSarcoma, KaposiViral Envelope ProteinsHumansAnimalsMiceCell LineCastleman DiseaseHerpesviridae InfectionsHEK293 CellsEndothelial Cells

Stichwörter der Autor:innen

K8.1KCPKSHV complement control proteinKaposi sarcoma-associated herpesvirusKaposicaNSG mouseORF4human herpesvirus-8humanized mouseinfectionviral entry

Substanzen

Viral ProteinsKSHV complement control protein, Herpesvirus 8Viral Envelope ProteinsK8.1 protein, Human herpesvirus 8

Autor:innen und Institutionen

  • Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA.
  • Irell & Manella Graduate School of Biological Sciences of City of Hope, Duarte, California, USA.
  • Department of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, Duarte, California, USA.

ORCID-Profile: Murali Muniraju, Gabriela M Escalante, Mafalda A Farelo, Javier Gordon Ogembo

Förderung

  • NIAID NIH HHS
  • HHS | National Institutes of Health (NIH)
  • NCI NIH HHS

Zitieren

APA

Muniraju, M., Mutsvunguma, L. Z., Reidel, I. G., Escalante, G. M., Cua, S., Musonda, W., Calero-Landa, J., Farelo, M. A., Rodriguez, E., Li, Z., & Ogembo, J. G. (2024). Kaposi sarcoma-associated herpesvirus complement control protein (KCP) and glycoprotein K8.1 are not required for viral infection in vitro or in vivo. Journal of Virology. https://doi.org/10.1128/jvi.00576-24

Vancouver

Muniraju M, Mutsvunguma LZ, Reidel IG, Escalante GM, Cua S, Musonda W, et al. Kaposi sarcoma-associated herpesvirus complement control protein (KCP) and glycoprotein K8.1 are not required for viral infection in vitro or in vivo. Journal of Virology. 2024. doi:10.1128/jvi.00576-24

BibTeX
@article{Muniraju2024,
  author = {Muniraju, Murali and Mutsvunguma, Lorraine Z and Reidel, Ivana G and Escalante, Gabriela M and Cua, Simeon and Musonda, Webster and Calero-Landa, Jonathan and Farelo, Mafalda A and Rodriguez, Esther and Li, Zhou and Ogembo, Javier Gordon},
  title = {Kaposi sarcoma-associated herpesvirus complement control protein (KCP) and glycoprotein K8.1 are not required for viral infection in vitro or in vivo},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.00576-24}
}
Kostenlos starten →